יחס חוב לטווח ארוך להון lisata.com (LSTA)

Lisata Therapeutics (LSTA) is developing innovative drug delivery methods for solid tumors, striving for scientific breakthroughs in the treatment of the pancreas. The long-term debt-to-equity ratio reflects financial stability, where the 0.00 mark indicates the level of credit leverage. Orphan drug designations strengthen the business, although rising state protectionism and sanctions on biomaterials could hinder the company's global expansion.

Asset managers require an accurate assessment of an issuer's financial stability to minimize risks. This metric compares liabilities with maturities exceeding one year against equity to reveal the degree of leverage. Analyzing the current long-term debt-to-equity ratio allows for the timely detection of credit load stagnation. This is critical for Lisata Therapeutics (LSTA), as stable royalties from the CendR platform must effectively cover long-term obligations.